GSK to work with NIH on Zika vaccine

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it is collaborating with NIH's Vaccine Research Center on laboratory studies of a Zika vaccine using the pharma's self-amplifying mRNA (SAM) technology, which the pharma said could lead to development of a clinical candidate. GSK inherited the vaccine technology from Novartis AG (NYSE:NVS; SIX:NOVN) as part of their asset swap in 2015. ...